Journal
CLINICAL AND EXPERIMENTAL IMMUNOLOGY
Volume 172, Issue 2, Pages 148-157Publisher
WILEY
DOI: 10.1111/cei.12038
Keywords
autoimmune disease; dendritic cells; immunotherapy; rheumatoid arthritis; tolerance
Categories
Funding
- Arthritis Research UK
- Medical Research Council (MRC)
- Biotechnology and Biological Sciences Research Council (BBSRC)
- J.G.W. Patterson Foundation
- National Institute for Health Research Newcastle Biomedical Research Centre based at Newcastle Hospitals Foundation Trust
- Newcastle University
- Versus Arthritis [18155] Funding Source: researchfish
Ask authors/readers for more resources
Dendritic cells with tolerogenic function (tolDC) have become a promising immunotherapeutic tool for reinstating immune tolerance in rheumatoid arthritis (RA) and other autoimmune diseases. The concept underpinning tolDC therapy is that it specifically targets the pathogenic autoimmune response while leaving protective immunity intact. Findings from human in-vitro and mouse in-vivo studies have been translated into the development of clinical grade tolDC for the treatment of autoimmune disorders. Recently, two tolDC trials in RA and type I diabetes have been carried out and other trials are in progress or are imminent. In this review, we provide an update on tolDC therapy, in particular in relation to the treatment of RA, and discuss the challenges and the future perspectives of this new experimental immunotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available